Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease. The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...
Patients with hepatitis C and Child-Pugh A cirrhosis had similar rates of treatment-related adverse events and lower rates of hepatic decompensation after treatment with Viekira Pak (Holkira Pak in Canada) compared with untreated patients, according to recently published data. However, those with a history of advanced cirrhosis were more likely to experience treatment-related adverse events. “Importantly, many of the events consistent with hepatic decompe
HealthDay News – There is a probable interaction between paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) [Holkira Pak / Viekira Pak] plus ribavirin with warfarin, according to a case report published online in the Journal of Clinical Pharmacy and Therapeutics. Gina M. Puglisi, PharmD., from VA Maine Healthcare System in Augusta, and colleagues present the case of a probable interaction between PrOD with ribavirin and warfarin in a 58-year-old patient w
US pharma major AbbVie (NYSE: ABBV) presented new data on Thursday on patients with genotype 1 chronic hepatitis C virus (HCV) infection who took Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir)--Holkira or Viekira Pak. Treated with or without ribavirin (RBV), they achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs). The d...
Current Treatments as of March 2018 IMPORTANT: As of March 13, 2018, anyone in B.C. living with this now-curable virus will have a choice of several treatment options – all of which are fully funded under PharmaCare, and all restrictions based on disease level have been removed. There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare. Many of the older combinations involve the use of int
Oct 22, 2015The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak [Holkira Pak in Canada] and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.Patients taking these medicines should contact their health care professional immediately if they develop fatigue
What a Christmas Present! On December 23, 2014, Health Canada approved AbbVie's new interferon-free hepatitis C combo! HOLKIRA™ PAK (known in the USA as VIEKIRA™ PAK) has an overall 97% success rate for genotype 1 patients in research trials. All patients, even those with compensated cirrhosis, take it for only 12 weeks EXCEPT genotype 1a cirrhotic patients who have had a previous null response to pegylated interferon (pegIFN) and ribavirin, who must take
AbbVie is now offering a discounted price in the USA on their new "3D" combo known as Viekira Pak™ via pharmacy "Express Scripts" - see below. Any doctor can prescribe it, not only specialists. And they are offering it without proof of a specified level of liver damage (no "F2+" requirements). This is a positive sign the anticipated "HCV treatment price wars" are beginning. We hope this trend spreads to Canada soon, though the pricing is still likely to b